Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 309 entries
Sorted by: Best Match Show Resources per page
Meningiomas.

Current treatment options in neurology

Chamberlain MC.
PMID: 11123860
Curr Treat Options Neurol. 2001 Jan;3(1):67-76. doi: 10.1007/s11940-001-0025-6.

Meningiomas are extra-axial brain tumors of middle-to-late adult life and show a predominance in women. Overall, 90% of meningiomas are benign, 6% atypical, and 2% are malignant. Most patients diagnosed with a meningioma decide to have it removed surgically,...

Cite
Chamberlain MC. Meningiomas. Curr Treat Options Neurol. 2001;3(1):67-76doi: 10.1007/s11940-001-0025-6.
Chamberlain, M. C. (2001). Meningiomas. Current treatment options in neurology, 3(1), 67-76. https://doi.org/10.1007/s11940-001-0025-6
Chamberlain. "Meningiomas." Current treatment options in neurology vol. 3,1 (2001): 67-76. doi: https://doi.org/10.1007/s11940-001-0025-6
Chamberlain MC. Meningiomas. Curr Treat Options Neurol. 2001 Jan;3(1):67-76. doi: 10.1007/s11940-001-0025-6. PMID: 11123860.
Copy Download .nbib Format: NLM
Intracerebral Meningiomas.

Current treatment options in neurology

Chamberlain MC.
PMID: 15157407
Curr Treat Options Neurol. 2004 Jul;6(4):297-305. doi: 10.1007/s11940-004-0029-0.

Meningiomas are extra-axial brain tumors of middle to late adult life, and they have a female predominance. Overall, 90% of meningiomas are benign, 6% are atypical, and 2% are malignant. Most patients diagnosed with a meningioma decide to have...

Cite
Chamberlain MC. Intracerebral Meningiomas. Curr Treat Options Neurol. 2004;6(4):297-305doi: 10.1007/s11940-004-0029-0.
Chamberlain, M. C. (2004). Intracerebral Meningiomas. Current treatment options in neurology, 6(4), 297-305. https://doi.org/10.1007/s11940-004-0029-0
Chamberlain, Marc C.. "Intracerebral Meningiomas." Current treatment options in neurology vol. 6,4 (2004): 297-305. doi: https://doi.org/10.1007/s11940-004-0029-0
Chamberlain MC. Intracerebral Meningiomas. Curr Treat Options Neurol. 2004 Jul;6(4):297-305. doi: 10.1007/s11940-004-0029-0. PMID: 15157407.
Copy Download .nbib Format: NLM
Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma.

Advances in hematology

Vakkalanka B, Link BK.
PMID: 21687649
Adv Hematol. 2011;2011:656013. doi: 10.1155/2011/656013. Epub 2011 May 02.

A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly used chemotherapy regime for Hodgkin lymphoma. This highly effective treatment is associated with a significant risk of neutropenia. Various strategies are adopted to counter...

Cite
Vakkalanka B, Link BK. Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Adv Hematol. 2011;2011:656013doi: 10.1155/2011/656013.
Vakkalanka, B., & Link, B. K. (2011). Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Advances in hematology, 2011656013. https://doi.org/10.1155/2011/656013
Vakkalanka, Bhanu, and Link, Brian K. "Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma." Advances in hematology vol. 2011 (2011): 656013. doi: https://doi.org/10.1155/2011/656013
Vakkalanka B, Link BK. Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. Adv Hematol. 2011;2011:656013. doi: 10.1155/2011/656013. Epub 2011 May 02. PMID: 21687649; PMCID: PMC3112508.
Copy Download .nbib Format: NLM
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration.

International journal of pharmaceutical compounding

Trissel LA, Zhang Y, Xu QA.
PMID: 23974237
Int J Pharm Compd. 2006 May-Jun;10(3):234-6.

The objective of this study was to evaluate the physical and chemical stability of mixtures of undiluted palonosetron hydrochloride 50 micrograms/mL with dacarbazine 4 mg/mL and with methylprednisolone sodium succinate 5 mg/mL in 5% dextrose injection during simulated Y-site...

Cite
Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration. Int J Pharm Compd. 2006;10(3):234-6
Trissel, L. A., Zhang, Y., & Xu, Q. A. (2006). Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration. International journal of pharmaceutical compounding, 10(3), 234-6.
Trissel, Lawrence A, et al. "Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration." International journal of pharmaceutical compounding vol. 10,3 (2006): 234-6.
Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration. Int J Pharm Compd. 2006 May-Jun;10(3):234-6. PMID: 23974237.
Copy Download .nbib Format: NLM
Dacarbazine mediate antimelanoma effects via NK cells.

Oncoimmunology

Hervieu A, Mignot G, Ghiringhelli F.
PMID: 23734324
Oncoimmunology. 2013 Apr 01;2(4):e23714. doi: 10.4161/onci.23714.

Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of

Cite
Hervieu A, Mignot G, Ghiringhelli F. Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology. 2013;2(4):e23714doi: 10.4161/onci.23714.
Hervieu, A., Mignot, G., & Ghiringhelli, F. (2013). Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology, 2(4), e23714. https://doi.org/10.4161/onci.23714
Hervieu, Alice, et al. "Dacarbazine mediate antimelanoma effects via NK cells." Oncoimmunology vol. 2,4 (2013): e23714. doi: https://doi.org/10.4161/onci.23714
Hervieu A, Mignot G, Ghiringhelli F. Dacarbazine mediate antimelanoma effects via NK cells. Oncoimmunology. 2013 Apr 01;2(4):e23714. doi: 10.4161/onci.23714. PMID: 23734324; PMCID: PMC3654594.
Copy Download .nbib Format: NLM
The evolution in melanoma treatment as a reflection of precision-oriented medicine.

Oncology letters

Kushnir I, Merimsky O.
PMID: 23420786
Oncol Lett. 2013 Feb;5(2):424-426. doi: 10.3892/ol.2012.1065. Epub 2012 Dec 05.

Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. Dacarbazine was accepted as the standard treatment for melanoma in the 1970s, and despite inducing an overall survival of approximately 7.4 months, it remained...

Cite
Kushnir I, Merimsky O. The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncol Lett. 2012;5(2):424-426doi: 10.3892/ol.2012.1065.
Kushnir, I., & Merimsky, O. (2013). The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncology letters, 5(2), 424-426. https://doi.org/10.3892/ol.2012.1065
Kushnir, Igal, and Merimsky, Ofer. "The evolution in melanoma treatment as a reflection of precision-oriented medicine." Oncology letters vol. 5,2 (2013): 424-426. doi: https://doi.org/10.3892/ol.2012.1065
Kushnir I, Merimsky O. The evolution in melanoma treatment as a reflection of precision-oriented medicine. Oncol Lett. 2013 Feb;5(2):424-426. doi: 10.3892/ol.2012.1065. Epub 2012 Dec 05. PMID: 23420786; PMCID: PMC3573132.
Copy Download .nbib Format: NLM
Rapid desensitization for brentuximab vedotin (Adceteris.

Clinical and molecular allergy : CMA

Di Girolamo A, Albanesi M, Sinisi A, Nettis E, Di Bona D, Caiaffa MF, Macchia L.
PMID: 30386181
Clin Mol Allergy. 2018 Oct 29;16:22. doi: 10.1186/s12948-018-0100-0. eCollection 2018.

BACKGROUND: Brentuximab vedotin (BV) is an antibody-drug conjugate formed by an anti-CD30 chimeric IgGCASE PRESENTATION: A 20-year old male patient was diagnosed with Hodgkin lymphoma in July 2014. The first line treatment with adriblastine, bleomicine, vinblastine and dacarbazine lead...

Cite
Di Girolamo A, Albanesi M, Sinisi A, et al. Rapid desensitization for brentuximab vedotin (Adceteris. Clin Mol Allergy. 2018;16:22doi: 10.1186/s12948-018-0100-0.
Di Girolamo, A., Albanesi, M., Sinisi, A., Nettis, E., Di Bona, D., Caiaffa, M. F., & Macchia, L. (2018). Rapid desensitization for brentuximab vedotin (Adceteris. Clinical and molecular allergy : CMA, 1622. https://doi.org/10.1186/s12948-018-0100-0
Di Girolamo, Attilio, et al. "Rapid desensitization for brentuximab vedotin (Adceteris." Clinical and molecular allergy : CMA vol. 16 (2018): 22. doi: https://doi.org/10.1186/s12948-018-0100-0
Di Girolamo A, Albanesi M, Sinisi A, Nettis E, Di Bona D, Caiaffa MF, Macchia L. Rapid desensitization for brentuximab vedotin (Adceteris. Clin Mol Allergy. 2018 Oct 29;16:22. doi: 10.1186/s12948-018-0100-0. eCollection 2018. PMID: 30386181; PMCID: PMC6205792.
Copy Download .nbib Format: NLM
Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy.

Case reports in oncology

Montana W, Buck DA, Smith T.
PMID: 29158727
Case Rep Oncol. 2017 Sep 06;10(3):795-801. doi: 10.1159/000479224. eCollection 2017.

Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior...

Cite
Montana W, Buck DA, Smith T. Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy. Case Rep Oncol. 2017;10(3):795-801doi: 10.1159/000479224.
Montana, W., Buck, D. A., & Smith, T. (2017). Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy. Case reports in oncology, 10(3), 795-801. https://doi.org/10.1159/000479224
Montana, Wilbur, et al. "Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy." Case reports in oncology vol. 10,3 (2017): 795-801. doi: https://doi.org/10.1159/000479224
Montana W, Buck DA, Smith T. Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy. Case Rep Oncol. 2017 Sep 06;10(3):795-801. doi: 10.1159/000479224. eCollection 2017. PMID: 29158727; PMCID: PMC5685419.
Copy Download .nbib Format: NLM
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.

ClinicoEconomics and outcomes research : CEOR

Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M.
PMID: 29563820
Clinicoecon Outcomes Res. 2018 Mar 08;10:139-154. doi: 10.2147/CEOR.S144208. eCollection 2018.

BACKGROUND: Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to reflect...

Cite
Gibson EJ, Begum N, Koblbauer I, et al. Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. Clinicoecon Outcomes Res. 2018;10:139-154doi: 10.2147/CEOR.S144208.
Gibson, E. J., Begum, N., Koblbauer, I., Dranitsaris, G., Liew, D., McEwan, P., Tahami Monfared, A. A., Yuan, Y., Juarez-Garcia, A., Tyas, D., & Lees, M. (2018). Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and outcomes research : CEOR, 10139-154. https://doi.org/10.2147/CEOR.S144208
Gibson, E J, et al. "Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes." ClinicoEconomics and outcomes research : CEOR vol. 10 (2018): 139-154. doi: https://doi.org/10.2147/CEOR.S144208
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Tahami Monfared AA, Yuan Y, Juarez-Garcia A, Tyas D, Lees M. Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. Clinicoecon Outcomes Res. 2018 Mar 08;10:139-154. doi: 10.2147/CEOR.S144208. eCollection 2018. PMID: 29563820; PMCID: PMC5848668.
Copy Download .nbib Format: NLM
Time trends of consumption and costs of drugs in a cancer referral centre.

International journal of oncology

Marfella A, Perrone F, Creazzola S, Salzano M, Monfardini S.
PMID: 21533426
Int J Oncol. 1997 Mar;10(3):641-4. doi: 10.3892/ijo.10.3.641.

This study is a descriptive analysis of the consumption and the costs of antineoplastic chemotherapeutic agents and of the major groups of drugs used for supportive therapy during the 1990-1995 period, at the National Cancer Institute of Naples, Italy....

Cite
Marfella A, Perrone F, Creazzola S, et al. Time trends of consumption and costs of drugs in a cancer referral centre. Int J Oncol. 1997;10(3):641-4doi: 10.3892/ijo.10.3.641.
Marfella, A., Perrone, F., Creazzola, S., Salzano, M., & Monfardini, S. (1997). Time trends of consumption and costs of drugs in a cancer referral centre. International journal of oncology, 10(3), 641-4. https://doi.org/10.3892/ijo.10.3.641
Marfella, A, et al. "Time trends of consumption and costs of drugs in a cancer referral centre." International journal of oncology vol. 10,3 (1997): 641-4. doi: https://doi.org/10.3892/ijo.10.3.641
Marfella A, Perrone F, Creazzola S, Salzano M, Monfardini S. Time trends of consumption and costs of drugs in a cancer referral centre. Int J Oncol. 1997 Mar;10(3):641-4. doi: 10.3892/ijo.10.3.641. PMID: 21533426.
Copy Download .nbib Format: NLM
Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance.

Cancer & metabolism

Malvi P, Chaube B, Singh SV, Mohammad N, Pandey V, Vijayakumar MV, Radhakrishnan RM, Vanuopadath M, Nair SS, Nair BG, Bhat MK.
PMID: 27980732
Cancer Metab. 2016 Dec 07;4:21. doi: 10.1186/s40170-016-0162-8. eCollection 2016.

BACKGROUND: Obesity-related cellular, metabolic, and molecular alterations have been shown to increase cancer risk and tumor progression and are associated with poorer therapeutic outcome in cancer patients. However, the impact of obesity and weight-control interventions on the therapeutic response...

Cite
Malvi P, Chaube B, Singh SV, et al. Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance. Cancer Metab. 2016;4:21doi: 10.1186/s40170-016-0162-8.
Malvi, P., Chaube, B., Singh, S. V., Mohammad, N., Pandey, V., Vijayakumar, M. V., Radhakrishnan, R. M., Vanuopadath, M., Nair, S. S., Nair, B. G., & Bhat, M. K. (2016). Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance. Cancer & metabolism, 421. https://doi.org/10.1186/s40170-016-0162-8
Malvi, Parmanand, et al. "Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance." Cancer & metabolism vol. 4 (2016): 21. doi: https://doi.org/10.1186/s40170-016-0162-8
Malvi P, Chaube B, Singh SV, Mohammad N, Pandey V, Vijayakumar MV, Radhakrishnan RM, Vanuopadath M, Nair SS, Nair BG, Bhat MK. Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance. Cancer Metab. 2016 Dec 07;4:21. doi: 10.1186/s40170-016-0162-8. eCollection 2016. PMID: 27980732; PMCID: PMC5142287.
Copy Download .nbib Format: NLM
Metastatic Malignant Paraganglioma: A Case Report and Review of Literature.

World journal of oncology

Prades CA, Atassi B, Nazeer H.
PMID: 29147442
World J Oncol. 2017 Jun;8(3):92-95. doi: 10.14740/wjon1033w. Epub 2017 Jun 09.

Metastasis is a rare presentation of non-secretory paraganglioma. Consequently, there is no standard of care for the treatment of metastatic malignant paraganglioma. The most widely used chemotherapy regimen for non-resectable cases includes cyclophosphamide, vincristine, and dacarbazine (CVD). CVD has...

Cite
Prades CA, Atassi B, Nazeer H. Metastatic Malignant Paraganglioma: A Case Report and Review of Literature. World J Oncol. 2017;8(3):92-95doi: 10.14740/wjon1033w.
Prades, C. A., Atassi, B., & Nazeer, H. (2017). Metastatic Malignant Paraganglioma: A Case Report and Review of Literature. World journal of oncology, 8(3), 92-95. https://doi.org/10.14740/wjon1033w
Prades, Carlo Angelo, et al. "Metastatic Malignant Paraganglioma: A Case Report and Review of Literature." World journal of oncology vol. 8,3 (2017): 92-95. doi: https://doi.org/10.14740/wjon1033w
Prades CA, Atassi B, Nazeer H. Metastatic Malignant Paraganglioma: A Case Report and Review of Literature. World J Oncol. 2017 Jun;8(3):92-95. doi: 10.14740/wjon1033w. Epub 2017 Jun 09. PMID: 29147442; PMCID: PMC5650004.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 309 entries